Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

FDA Approves Cymbalta® for the Management of Chronic Musculoskeletal Pain

November 4, 2010 By Bio-Medicine.Org

INDIANAPOLIS, Nov. 4, 2010 /PRNewswire-FirstCall/ — Eli Lilly
and Company (NYSE:
LLY
) announced that the U.S. Food and Drug Administration (FDA)
has approved Cymbalta® (duloxetine HCl) for the management of
chronic musculoskeletal pain. This has been established in studies
in patients with chronic low back pain and chronic pain due to
osteoarthritis. This is the fifth indication the FDA has approved
for Cymbalta.

Cymbalta, which has been shown to significantly reduce chronic
low back pain and chronic pain due to osteoarthritis, is a
non-narcotic pain reliever that is meant to be taken once a day,
every day by people with these pain conditions.

“People with chronic musculoskeletal pain often struggle to find
a medication that works for them. The approval of Cymbalta for
chronic musculoskeletal pain by the FDA gives doctors another
option to help an underserved and suffering group of patients,”
said Michael Clark, M.D., MPH, director, Chronic Pain Treatment
Program, Department of Psychiatry and Behavioral Sciences, The
Johns Hopkins Medical Institutions.

Although the exact way that Cymbalta works to reduce chronic
musculoskeletal pain is unknown, it is believed that Cymbalta helps
lessen pain by enhancing the body’s natural pain suppressing system
by increasing the activity of serotonin and norepinephrine in the
brain and spinal cord.

In chronic musculoskeletal pain clinical studies, the most
commonly observed adverse events (those occurring in at least 5
percent of study participants taking Cymbalta and at least twice
the rate of placebo) in Cymbalta-treated patients with chronic low
back pain were nausea, dry mouth, insomnia, sleepiness,
constipation, dizziness and fatigue. The most commonly observed
adverse events in Cymbalta-treated patients with chronic pain due
to osteoarthritis were nausea, fatigue and constipation.

“It’s important that p

‘/>”/>

SOURCE

Related Articles Read More >

DeepWell Digital Therapeutics Mike Wilson Ryan Douglas
How DeepWell is developing video games as tools for treating medical conditions
A woman with a small, handheld device in her lap with tubes that look like earphones plugged into her ears.
Ear-puffing device for migraine treatment wins FDA breakthrough designation
Abbott
Abbott launches upgraded digital health app for neurostimulation
Catheter delivery could enable better brain implants: Synchron’s neuroscience chief explains how

DeviceTalks Weekly.

May 13, 2022
Our Pre-Post-DeviceTalks Boston episode, also MedtronicTalks replay with Gastro CMO Austin Chiang
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech